Fosun Karry Secures New Round of Financing and Advances CAR-T and Stem Cell Pipeline

Recently, Fosun Kite secured a new round of financing, which was jointly completed by Shum Yip Capital under Shum Yip Group, Fushan Capital, Pingshan Guidance Fund, and Kunpeng Capital.

Fosun Kite was established in 2017 as a joint venture between Fosun Pharma and Kite Pharma, originally named Fosun Kite Biotechnology. In September 2024, Fosun Pharma completed its acquisition of full ownership of the company and renamed it Fosun Kite the following month. As Fosun Pharma’s core platform in the field of cell therapy, Fosun Kite is primarily responsible for the research and development, manufacturing, and commercialization of related products. Its flagship product, axicabtagene ciloleucel injection, is the first CAR-T therapy approved for marketing in China. It has currently been approved for the treatment of large B-cell lymphoma in second-line or later and third-line or later settings. Meanwhile, a bridging clinical trial for the third indication of this product in non-Hodgkin lymphoma is underway in China, and it has been included in the Breakthrough Therapy Designation program.

In addition, the marketing application for the company’s second CAR-T product, brexucabtagene autoleucel injection (code: FKC889), was accepted by the National Medical Products Administration in September 2025. It is primarily indicated for the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia.

In addition to its CAR-T products, Fosun Kite is also expanding into other cell therapy areas. In January 2026, the company entered into a strategic partnership with Sibiman Biologics, securing exclusive commercialization rights for the latter’s core product, AlloJoin (a stem cell drug for knee osteoarthritis), in mainland China, Hong Kong, and Macau. By May of the same year, the pivotal Phase III clinical trial of this drug had successfully completed enrollment of more than 500 patients. Sibiman Biologics plans to announce the study data in 2027 and subsequently submit a new drug application for market approval.

Approval Rate Below 10%! First-Month Filing Data for Regulation 818 Released

Launch of the National Science and Technology Major Project “Development and Clinical Translation of Novel In Vivo CAR-T Therapeutics”

RMB 20 Million! A Cell Reprogramming Patent of Guangxi Academy of Medical Sciences Successfully Commercialized

A Domestic Nucleic Acid Drug Startup Completes Angel+ Round Financing

Western China’s First In-Hospital Cell Therapy “Super Factory” Fully Operational

Over RMB 1.1 Billion Invested! Sartorius’ Newly Built CGT Capability Center Officially Commences Operations

First Biomedical New Technology Project Involving Neural Cells Completes Filing Following Implementation of Order No. 818

Xueji Biotech Completes Over RMB 100 Million in Series B Second-Close Financing

Declaration:ReferenceDomesticRongComeSource: Official Media/Online News, this publicOfficial AccountAimed atKnowledge sharing, maintaining neutrality regarding the content, statements, and views reprinted or shared, without endorsing their accuracyNo express or implied warranties are made regarding the accuracy, reliability, or completeness of the content, which is provided for readers’ reference only.